Last reviewed · How we verify
SPC3649
At a glance
| Generic name | SPC3649 |
|---|---|
| Sponsor | Santaris Pharma A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection (PHASE2)
- Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C (PHASE2)
- Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects (PHASE1)
- Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects (PHASE2)
- SPC3649 Multiple Dose Study in Healthy Volunteers (PHASE1)
- Safety Study of SPC3649 in Healthy Men (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPC3649 CI brief — competitive landscape report
- SPC3649 updates RSS · CI watch RSS
- Santaris Pharma A/S portfolio CI